TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06114147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: trans thoracic echocardiography measure
Description: The trans thoracic echography would be carried out with cardiac classic sections to ensure the structural cardiac and valvular normality and then sections repeated 3 times over 10 minutes will be carried out to calculate the cardiac output.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICON measure
Description: The ICON will be placed at the beginning of the consultation and the measurements will be taken at the same time as the trans thoracic ultrasound in the left lateral decubitus position.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: USCOM
Description: Afterwards, measurements will be made with USCOM in left lateral position and 3 of the best spectra archived according to the Fremantle score.
Study: NCT05157490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: Guided meditations in the preoperative time period, at least 3 sessions per week, leading up to surgery
Study: NCT05185960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALLSWEET®
Description: ALLSWEET®, is a non-GMO certified allulose developed by the study sponsor. It will be diluted in water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALLSWEET® and sucrose
Description: ALLSWEET®, is a non-GMO certified allulose developed by the study sponsor. It will be added to sucrose (table sugar) and diluted in water.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: Table sugar. It will be consumed by diluting it in water.
Study: NCT05315518

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: single-shade universal resin composite (omnichroma) with blocker( omnichroma blocker)
Description: (OMNICHROMA BLOCKER) is indicated for preventing shade-matching interference in Class IV restorations, Masking dark dentition and dentin. In cases where there is a lack of tooth structure to bond to, (BLOCKER) works as a supplementary product to provide a lingual wall to the restoration, prevent shade-match obstruction and mask staining.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: single-shade universal resin composite (omnichroma) with blocker( omnichroma blocker)
Description: (OMNICHROMA BLOCKER) is indicated for preventing shade-matching interference in Class IV restorations, Masking dark dentition and dentin. In cases where there is a lack of tooth structure to bond to, (BLOCKER) works as a supplementary product to provide a lingual wall to the restoration, prevent shade-match obstruction and mask staining.
Study: NCT05825937

Intervention type: DEVICE
Intervention: ClearSight System
Description: Patients having either elective cardiac surgery or elective neurointerventional surgery will have blood pressure monitored by the ClearSight device, along with the standard of care radial arterial line, throughout their surgery. The arterial line will be placed on the radial artery contralateral to the upper arm blood pressure cuff. The ClearSight device will then be placed on the third finger of the hand ipsilateral to the radial arterial line.

Intervention type: DEVICE
Intervention: ClearSight System
Description: Patients having either elective cardiac surgery or elective neurointerventional surgery will have blood pressure monitored by the ClearSight device, along with the standard of care radial arterial line, throughout their surgery. The arterial line will be placed on the radial artery contralateral to the upper arm blood pressure cuff. The ClearSight device will then be placed on the third finger of the hand ipsilateral to the radial arterial line.
Study: NCT05920421

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: diaghragm affection by ultrasound before and after the blocks
Description: the participant will assess diaphragm sparing in each block and evaluate effectiveness of infraclavicular subomohyoid blocks and subomohyoid subscapularis blocks according to intraoperative and postoperative analgesia and diaphragm affection and comparing them with interscalen and with each others

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diaghragm affection by ultrasound before and after the blocks
Description: the participant will assess diaphragm sparing in each block and evaluate effectiveness of infraclavicular subomohyoid blocks and subomohyoid subscapularis blocks according to intraoperative and postoperative analgesia and diaphragm affection and comparing them with interscalen and with each others

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diaghragm affection by ultrasound before and after the blocks
Description: the participant will assess diaphragm sparing in each block and evaluate effectiveness of infraclavicular subomohyoid blocks and subomohyoid subscapularis blocks according to intraoperative and postoperative analgesia and diaphragm affection and comparing them with interscalen and with each others
Study: NCT04979169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: A series of theory-informed text messages encouraging them to contact their primary care provider and the UR LCS Program's Patient Navigator to coordinate screening, along with contact information to do so.
Study: NCT04315337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Kitchen Training
Description: VR Training will include repeated practice of a single, everyday task in a non-immersive VR context (e.g., VR Breakfast) using a laptop with a touch-screen interface for four days over the course of one week.
Study: NCT06490328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKF-MA102
Description: Administered twice at 12-week intervals
Study: NCT04859751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB4-845 Injection
Description: Intravesical administration of VB4-845 Injection.
Study: NCT06038279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INI-2004
Description: INI-2004 (a toll-like receptor \[TLR\]4 agonist) liposomal formulation. INI-2004 is an intranasal (IN) TLR4 agonist that is targeted to prevent AR symptoms in subjects with seasonal AR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INI-2004
Description: INI-2004 (a toll-like receptor \[TLR\]4 agonist) liposomal formulation. INI-2004 is an intranasal (IN) TLR4 agonist that is targeted to prevent AR symptoms in subjects with seasonal AR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INI-2004
Description: INI-2004 (a toll-like receptor \[TLR\]4 agonist) liposomal formulation. INI-2004 is an intranasal (IN) TLR4 agonist that is targeted to prevent AR symptoms in subjects with seasonal AR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INI-2004
Description: INI-2004 (a toll-like receptor \[TLR\]4 agonist) liposomal formulation. INI-2004 is an intranasal (IN) TLR4 agonist that is targeted to prevent AR symptoms in subjects with seasonal AR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INI-2004
Description: INI-2004 (a toll-like receptor \[TLR\]4 agonist) liposomal formulation. INI-2004 is an intranasal (IN) TLR4 agonist that is targeted to prevent AR symptoms in subjects with seasonal AR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INI-2004
Description: INI-2004 (a toll-like receptor \[TLR\]4 agonist) liposomal formulation. INI-2004 is an intranasal (IN) TLR4 agonist that is targeted to prevent AR symptoms in subjects with seasonal AR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INI-2004
Description: INI-2004 (a toll-like receptor \[TLR\]4 agonist) liposomal formulation. INI-2004 is an intranasal (IN) TLR4 agonist that is targeted to prevent AR symptoms in subjects with seasonal AR.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Placebo for INI-2004 is a clear, colorless solution free of particles supplied in 10 mL glass vials with a 10 mL fill.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Placebo for INI-2004 is a clear, colorless solution free of particles supplied in 10 mL glass vials with a 10 mL fill.
Study: NCT05824533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: onlay patella button
Description: Total knee arthroplasty (TKA) with a patella onlay button placed with a CORI Robotics System based on pre-operative 4DCT-imaging.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional procedure; NO onlay patella button
Description: Total knee arthroplasty (TKA) placed with a CORI Robotics System based on pre-operative 4DCT-imaging.
Study: NCT06127992

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold stimulation tests / critical temperature threshold
Description: ICT was performed following a standard protocol. Briefly, a melting ice cube in thin plastic bag was placed on the volar surface of the patient forearm for 5 min, with macroscopic assessment of the test site 10 min later. TempTest® CSTs were done with TempTest® 4.0 (Courage \& Khazaka, Cologne, Germany), which has a single Peltier element (length: 350 mm, width: 2 mm) that provides a continuous temperature gradient from 4°C to 44°C. The use of TempTest® allows for reproducible and standardized cold (and heat) provocation tests and the identification of CTTs. TempTest® CST results were also assessed 10 min after the end of cold exposure.

Intervention type: DEVICE
Group type: OTHER
Intervention: Cold stimulation tests / critical temperature threshold
Description: ICT was performed following a standard protocol. Briefly, a melting ice cube in thin plastic bag was placed on the volar surface of the patient forearm for 5 min, with macroscopic assessment of the test site 10 min later. TempTest® CSTs were done with TempTest® 4.0 (Courage \& Khazaka, Cologne, Germany), which has a single Peltier element (length: 350 mm, width: 2 mm) that provides a continuous temperature gradient from 4°C to 44°C. The use of TempTest® allows for reproducible and standardized cold (and heat) provocation tests and the identification of CTTs. TempTest® CST results were also assessed 10 min after the end of cold exposure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold stimulation tests / critical temperature threshold
Description: ICT was performed following a standard protocol. Briefly, a melting ice cube in thin plastic bag was placed on the volar surface of the patient forearm for 5 min, with macroscopic assessment of the test site 10 min later. TempTest® CSTs were done with TempTest® 4.0 (Courage \& Khazaka, Cologne, Germany), which has a single Peltier element (length: 350 mm, width: 2 mm) that provides a continuous temperature gradient from 4°C to 44°C. The use of TempTest® allows for reproducible and standardized cold (and heat) provocation tests and the identification of CTTs. TempTest® CST results were also assessed 10 min after the end of cold exposure.
Study: NCT04712773

Intervention type: DEVICE
Group type: OTHER
Intervention: PMD-200 monitor
Description: Patient is connected to non-invasive PMD-200 monitor, measuring Nociception Level

Intervention type: DEVICE
Group type: OTHER
Intervention: Surgical Pleth Index monitor
Description: Patient is connected to non-invasive monitor measuring Surgical Pleth Index
Study: NCT05629806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin plus pioglitazone
Description: After the screening period, eligible subjects were admitted to two tablets of fixed mixture of metformin plus pioglitazone (15mg pioglitazone plus 500mg metformin) for 12 weeks. Then the subjects were titrated onto the alternative treatment of 50mg acarbose three times daily for 12 weeks. During this timeframe, all patients were instructed to monitor their blood glucose fluctuations with a FreeStyle Libre Pro Sensor (FGM system) before and after the study and the time point of drug replacement.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin plus pioglitazone
Description: After the screening period, eligible subjects were admitted to two tablets of fixed mixture of metformin plus pioglitazone (15mg pioglitazone plus 500mg metformin) for 12 weeks. Then the subjects were titrated onto the alternative treatment of 50mg acarbose three times daily for 12 weeks. During this timeframe, all patients were instructed to monitor their blood glucose fluctuations with a FreeStyle Libre Pro Sensor (FGM system) before and after the study and the time point of drug replacement.
Study: NCT06325007

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Induction of labor
Description: The study group only will drink a mixture of 60 ml of castor oil mixed with 140 ml of orange juice. Thirty minutes later, in both groups, an extraamniotic single balloon catheter will be inserted above the internal cervical os and filled with 60 mL of normal saline. Following removal, artificial rupture of the membranes will be performed as long as it is safe with regards to fetal head position. Oxytocin infusion will be commenced at once if contraction has not begun spontaneously (2 to 3 regular uterine contractions per 10 minutes). Continuous electronic fetal monitoring will be used throughout labor. Labor will be managed by the attending obstetricians and midwives. Labor progress abnormalities will be diagnosed and managed according to the department protocol based on the recommendations of the American College of Obstetricians and Gynecologists.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Induction of labor
Description: The study group only will drink a mixture of 60 ml of castor oil mixed with 140 ml of orange juice. Thirty minutes later, in both groups, an extraamniotic single balloon catheter will be inserted above the internal cervical os and filled with 60 mL of normal saline. Following removal, artificial rupture of the membranes will be performed as long as it is safe with regards to fetal head position. Oxytocin infusion will be commenced at once if contraction has not begun spontaneously (2 to 3 regular uterine contractions per 10 minutes). Continuous electronic fetal monitoring will be used throughout labor. Labor will be managed by the attending obstetricians and midwives. Labor progress abnormalities will be diagnosed and managed according to the department protocol based on the recommendations of the American College of Obstetricians and Gynecologists.
Study: NCT05891483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1905 Injection
Description: SHR-1905 Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1905 Injection
Description: SHR-1905 Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1905 Injection
Description: SHR-1905 Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR-1905 Placebo Injection
Description: SHR-1905 Placebo Injection
Study: NCT05064033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pragmatic Set of intervention and posterior capsular stretch
Description: Group 1 will receive a pragmatic set of interventions, including Serratus Anterior Stretch,Rotator Cuff Facilitation,Acromilcalavicular joint Mobilization,Stretch of Pectoralis Major and Minor,Thoracic Manipulation and posterior capsular stretch.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pragmatic Set of intervention and Sleeper Stretch
Description: Group 2 will receive a pragmatic set of interventions, including Serratus Anterior Stretch, Rotator Cuff Facilitation, Acromilcalavicular joint Mobilization, Stretch of Pectoralis Major and Minor, Thoracic Manipulation and sleeper stretch.
Study: NCT05319795

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effortful Swallow Maneuver
Description: Repeated practice of the Effortful Swallowing Maneuver generated by pushing the tongue with increased effort against the palate at the point of swallow initiation.
Study: NCT04682184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Description: Administered orally.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Biosensor Patch Device
Description: Biosensor patch device attached to the chest and worn throughout the trial with replacement of biosensor every 7 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Biosensor Patch Device
Description: Biosensor patch device attached to the chest and worn throughout the trial with replacement of biosensor every 7 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Biosensor Patch Device
Description: Biosensor patch device attached to the chest and worn throughout the trial with replacement of biosensor every 7 days.
Study: NCT05953454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience Education
Description: A pain neuroscience education session geared towards fear-avoidance beliefs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience Education
Description: A pain neuroscience education session geared towards fear-avoidance beliefs
Study: NCT05629806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: After the screening period, eligible subjects were admitted to 50mg acarbose three times daily for 12 weeks. Then the subjects were titrated onto the alternative treatment of two tablets of fixed mixture of metformin plus pioglitazone (15mg pioglitazone plus 500mg metformin) for 12 weeks. During this timeframe, all patients were instructed to monitor their blood glucose fluctuations with a FreeStyle Libre Pro Sensor (FGM system) before and after the study and the time point of drug replacement.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: After the screening period, eligible subjects were admitted to 50mg acarbose three times daily for 12 weeks. Then the subjects were titrated onto the alternative treatment of two tablets of fixed mixture of metformin plus pioglitazone (15mg pioglitazone plus 500mg metformin) for 12 weeks. During this timeframe, all patients were instructed to monitor their blood glucose fluctuations with a FreeStyle Libre Pro Sensor (FGM system) before and after the study and the time point of drug replacement.
Study: NCT04345588

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone injection
Description: we use injection lignocaine 10 mL, injection bupivacaine 0.5% 20 mL, 5 mL normal saline (NS). In group , injection dexamethasone 0.05 mg/kg will be added to the solution along with IV NS 1cc while the other group will receive 0.05 mg/kg injection dexamethasone intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone injection
Description: we use injection lignocaine 10 mL, injection bupivacaine 0.5% 20 mL, 5 mL normal saline (NS). In group , injection dexamethasone 0.05 mg/kg will be added to the solution along with IV NS 1cc while the other group will receive 0.05 mg/kg injection dexamethasone intravenously.
Study: NCT05458544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Ludotadipep 3.7 GBq
Description: Phase 1:~Patients will receive a single dose of 3.7 GBq of \[177Lu\]Ludotadipep~* Test article code/name: \[177Lu\]Ludotadipep~* Administration route: intravenous injection~* Total dose strength: 3.7 GBq~* Dosage form: solution for injection~Phase 2a:~Patients will receive 3.7 GBq of \[177Lu\]Ludotadipep every 8 \[±1\] weeks (4 to 6 times)~* Test article code/name: \[177Lu\]Ludotadipep~* Administration route: intravenous injection~* Total dose strength: 4 to 6 x 3.7 GBq~* Dosage form: solution for injection
Study: NCT05446012

Intervention type: DIAGNOSTIC_TEST
Intervention: thyroid function tests
Description: blood sample for thyroid function tests (TSH,T3,T3,Anti peroxidase antibody, anti thyroglobulin antibody)

Intervention type: DIAGNOSTIC_TEST
Intervention: thyroid function tests
Description: blood sample for thyroid function tests (TSH,T3,T3,Anti peroxidase antibody, anti thyroglobulin antibody)
Study: NCT06582992

Intervention type: OTHER
Intervention: RRBS
Description: Measure of genomic regions with differentially methylated profiles and differentially expressed protein

Intervention type: OTHER
Intervention: RRBS
Description: Measure of genomic regions with differentially methylated profiles and differentially expressed protein

Intervention type: OTHER
Intervention: RRBS
Description: Measure of genomic regions with differentially methylated profiles and differentially expressed protein
Study: NCT04862910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinect Based Virtual Reality Training
Description: The participant will receive the game instructions from the examiner.Protocol will be implemented 3 steps Warm Up phase Activity phase and cool down phase. The games will be played under the supervision and guidance of the therapist.Games are selected from Kinect games Kinect Sports Kinect Adventures and Your Shape Fitness Evolved. Three treatment sessions per week will be given to each participant. Total duration of each treatment session will be 45 Minutes.Participants will be instructed to walk outdoors for 30 Minutes daily. Routine Medication and routine diet will be continued.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: * They will be instructed to walk outdoors daily for 30 Minutes.~* They will continue their daily activities with a routine diet and routine Medication
Study: NCT03455725

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CardiAMP Cell Therapy System
Description: The CardiAMP Cell Therapy system consists of the CardiAMP Potency Assay, the Helix/Morph intramyocardial delivery catheter system, and the CardiAMP Cell Separator. The system allows the investigator to identify patients with a high chance to respond to im autologous stem cell therapy (using the CardiAMP Cell Potency Assay), to isolate the stem cells from a bone marrow harvest at the point of care (using the CardiAMP CS system), and to percutaneously inject the autologous cells into the myocardium using the Helix/Morph delivery catheters.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: Patients will receive sham bone marrow procedure and a ventriculogram. A scripted sham percutaneous procedure will be performed
Study: NCT05167799

Intervention type: DEVICE
Intervention: Cardiac Contractility Modulation (CCM)
Description: Patients will be implanted with CCM device according to indications, to improve Heart Failure symptoms and then enrolled in the Registry if they fullfil Inclusion and Exclusion Criteria (First of all if they are diagnosed with TTR Amyloidosis)
Study: NCT01223053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoprofen 10% cream
Description: 100 mg (10%) in 1 gram of topical cream applied three times per day for 7 days. Safety follow up on day 14.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo cream containing identical constituents as the active comparator except for ketoprofen
Study: NCT05020236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: subcutaneous
Study: NCT06506890

Intervention type: OTHER
Group type: OTHER
Intervention: Use of C-Polar coated HVAC Filter versus conventional HVAC Filter
Description: comparing the difference in reduction of bioaerosols between HVAC filters.